Medicines advice

Search Filters

Know what you're looking for?

Submission type

British National Formulary - Chapter

Pharmaceutical company

From

To

Advice

Accepted Not recommended Restricted Superseded Withdrawn Interim acceptance

Process

End of life/orphan Ultra orphan

Additional Details

Patient Access Scheme

Advanced Search

SMC ID	Date	Medicine	Submission Type	Indication
SMC2248	12/10/2020	avelumab (Bavencio)	Full	In combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
SMC2247	07/09/2020	pembrolizumab (Keytruda)	Full	In combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.
855/13	11/11/2013	axitinib (Inlyta)	Resubmission	For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

No medicines have been found.